American Diabetes Association
Online-Only Supplemental Material.pdf (215.27 kB)

Glomerular hyperfiltration predicts kidney function decline and mortality in type 1 and type 2 diabetes: a 21-year longitudinal study

Download (215.27 kB)
posted on 2023-02-15, 01:21 authored by Diego Moriconi, Luca Sacchetta, Martina Chiriacò, Lorenzo Nesti, Giovanna Forotti, Andrea Natali, Anna Solini, Domenico TricoDomenico Trico


Objective. To evaluate the prognostic value of glomerular hyperfiltration on long-term kidney-related outcomes and mortality in subjects with diabetes.

Methods. We retrospectively analyzed 21-year longitudinal data from 314 patients with long-standing type 2 or type 1 diabetes. Glomerular hyperfiltration was identified based on the age- and sex-specific distribution of the glomerular filtration rate measured by 99mTc-DTPA dynamic renal scintigraphy (mGFR). The primary outcome was a composite of doubling of serum creatinine, end-stage kidney disease (ESKD), or cardiorenal death. The kidney-specific outcome was a composite of doubling of serum creatinine, ESKD, or renal death.

Results. Over a median of 21.0 years, the primary composite outcome occurred in 25 (39.7%), 24 (38.1%), and 46 (24.5%) participants with high (H-mGFR, n=63), low (L-mGFR, n=63), or normal glomerular filtration (N-mGFR, n=188), respectively. Compared with N-mGFR, the hazard ratio [95% confidence interval] for the primary composite outcome was 2.09 [1.25–3.49] in H-mGFR and 1.81 [1.05–3.16] in L-mGFR. The hazard ratio for the kidney-specific composite outcome was 4.95 [2.21–11.09] in H-mGFR and 3.81 [1.70–8.56] in L-mGFR. The hazard ratios for doubling of serum creatinine and cardiorenal death were 4.86 [2.18–10.90] and 2.18 [1.24–3.83] in H-mGFR, respectively, and 4.04 [1.77–9.20] and 2.26 [1.27–4.01] in L-mGFR. 

Conclusions. Glomerular hyperfiltration, similar to hypofiltration, increases the combined risk of worsening kidney function and mortality from cardiovascular or renal causes in patients with diabetes. These findings encourage the active screening of these patients to optimize risk stratification and treatment of subclinical kidney disease.  


European Foundation for the Study of Diabetes Future Leaders Mentorship Programme Rising Star Fellowship